Crestor and strong non-US growth settle AstraZeneca
This article was originally published in Scrip
AstraZeneca reported that strong revenue growth in non-US markets during 2010 offset the loss of more than $1.6 billion of US revenue from generic competition on several products and the absence of H1N1 pandemic influenza vaccine revenue. Higher sales of the cholesterol treatment Crestor, in particular, kept full year revenues flat at $33.3 billion.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.